June 11 @ 11:00 AM – 12:00 PM
Join QIAGEN for a BioInsights-hosted webinar on June 11 to hear from Ryan Massopust, a Scientist at Asklepios BioPharmaceutical, Inc. (AskBio), about his use of quadruplex digital PCR (dPCR) to evaluate genome integrity and heterogeneity in target-based AAV genome variants.
As the gene therapy field rapidly grows, the need for product-specific analytics becomes crucial. Traditional quality attributes often fail to correlate consistently with drug potency or safety. It is believed that the heterogeneity of packaged genomes plays a role in this inconsistency. To address this, a quadruplex dPCR assay using four primer probe sets that cover the genome from promoter to poly(A) signal sequence was developed. This innovative genome integrity analysis allows for the precise calculation of both the absolute number and distribution (heterogeneity) of AAV genome variants. Complementary techniques such as long-read next generation sequencing (NGS) and analytical ultracentrifugation (AUC) can be used alongside this method to provide a thorough characterization of AAV drug products.
During this webinar, you will:
- Explore the unique advantages and current limitations of dPCR genome integrity assays.
- Gain a deeper understanding of digital PCR technology and its applications in cell and gene therapy.
- Discover the importance of characterizing genome heterogeneity for gene therapy drug products.
Don’t miss this opportunity to enhance your knowledge and stay ahead in the field of gene therapy!